News
Media
Conferences
Publication
Job Board
CME/CE
Partners
Editorial
Resources
Subscribe

Spotlight -

Long-Acting Injectable Therapy in the Management of Adult Patients with Schizophrenia|

Major Depressive Disorder

Opinion|Videos|August 9, 2024

MDMA-Assisted Therapy: Providing the Brain With a Necessary Boost

Author(s)John J. Miller, MD

The Psychiatric Times editor-in-chief shares perspectives on how a novel treatment, MDMA-assisted therapy, can potentially change the treatment landscape and improve patients’ lives.

Episodes in this series

John J. Miller, MD

EP. 1 The Evolution of PTSD Diagnosis and Treatment

John J. Miller, MD

EP. 2 MDMA-Assisted Therapy: Providing the Brain With a Necessary Boost

John J. Miller, MD

EP. 3 The Challenges of PTSD Symptom Clusters

John J. Miller, MD

EP. 4 Unmet Needs and the PTSD Treatment Pipeline

John J. Miller, MD

EP. 5 Do No Harm: Providing Guardrails for Effective PTSD Treatments

John J. Miller, MD

EP. 6 The Harms and Consequences of Untreated PTSD

PTSD

EP. 7 5 Key Take-Aways About PTSD Treatment: A Closer Look at MDMA

Newsletter

Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.

Related Content

Investigational Psilocybin for PTSD and Ongoing Trials

Investigational Psilocybin for PTSD and Ongoing Trials

ByGary W. Small, MD

February 5th 2026

anxiety negative allosteric modulator

Data Supports Potential of Negative Allosteric Modulators for Anxiety and Fear-Related Disorders

ByJessica Walters

February 4th 2026

FDA Accepts Investigational New Drug Application for COMP360 for PTSD

ByHeidi Anne Duerr, MPH

January 7th 2026

PTSD

Planned FDA Investigational New Drug Application: SPC-15 for the Treatment of PTSD

November 17th 2025

placebo

Placebo Response Rates Vary Across Psychiatric Disorders

ByMasha Impallaria, MD,Ahmed Sakr, MD,Haley Schuster, MD,Mark Mullen, MD,Rajesh R. Tampi, MD, MS, DFAPA, DFAAGP

November 12th 2025

Latest CME

Managing Negative Symptoms of Schizophrenia: Can Prescription Digital Therapeutics Make an Impact?

Managing Negative Symptoms of Schizophrenia: Can Prescription Digital Therapeutics Make an Impact?

Michael Asbach, DMSc, PA-C; Erin Crown, MHS, PA-C, Psych-CAQ

Optimizing Care for Patients With Tardive Dyskinesia

Optimizing Care for Patients With Tardive Dyskinesia

Amber Hoberg, MSN, APRN, PMHNP-BC; Erin Crown, PA-C, Psych-CAQ

Stabilize and Thrive: Prioritizing Patient Success Through Novel Therapeutic Management in Schizophrenia

Stabilize and Thrive: Prioritizing Patient Success Through Novel Therapeutic Management in Schizophrenia

Jonathan Meyer, MD; Jacob Hanaie, PharmD, APh, BCPP; Sanjai Rao, MD, DFAPA

Trending on Psychiatric Times

Depression and Long COVID Outcomes in Women: New Data Analysis

Presenting Our February 2026 Theme: Bipolar Disorder

Investigational Psilocybin for PTSD and Ongoing Trials

Patterns of Propensity: A Review of Heinrichs’ How Psychiatrists Make Decisions

In Memoriam: Elise Snyder, MD, A Legacy of Mentoring to Psychotherapists in China